Lonza Drops on Roche Drug Copy Testing Concerns: Zurich Mover Businessweek Teva and Lonza have not started phase III trials for rituximab, a generic copy of Rituxan, Dirk Oehlers, a spokesman for Lonza, said by telephone. The company is evaluating how to move forward with testing as the regulatory environment for biosimilars, ... |
